Business
KKR Announces Strategic Acquisition of HealthCare Royalty Partners, Expanding the Firm’s Health Care Franchise and Enhancing its Life Sciences Strategy
NEW YORK, July 30, 2025--KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. This strategic partnership will enable KKR to enhance its capabilities in biopharma royalty and credit investing, while expanding the firm’s existing footprint in the life sciences ecosystem.
About this update from Kkr & Co. Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/658d1edcf20066eafc5de5f7c4809462"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3DKq1iRuJLF7E4nUmpm7SQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/658d1edcf20066eafc5de5f7c4809462","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7maoj72QBYge09cGy3to9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/658d1edcf20066eafc5de5f7c4809462","width":1024,"height":512}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/9cb13f116bd3799f32f74d5e67bc0281"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6IycS1HHzgsyqsw1r_aqYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQxODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9cb13f116bd3799f32f74d5e67bc0281","width":480,"height":209}}},{"type":"text","content":"NEW YORK, July 30, 2025--(BUSINESS WIRE)--KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. This strategic partnership will enable KKR to enhance its capabilities in biopharma royalty and credit investing, while expanding the firm’s existing footprint in the life sciences ecosystem.","length":439,"tagName":"p"},{"type":"text","content":"Founded in 2006 and headquartered in Stamford, Connecticut, HCRx has a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets. Since inception, the firm has committed over $7 billion in capital and today manages approximately $3 billion in assets with a portfolio that spans over 10 therapeutic areas and over 55 products. HCRx’s deep expertise in royalty monetizations, private debt and corporate financing solutions presents significant opportunity given the biopharma royalties market is currently addressing only a small portion of total biopharma capital needs.","length":615,"tagName...